



**Peter Kästner**

**Contact**

Peter Kästner

## Publications (5)

De Marchis G, Krisai P, Werlen L, Sinnecker T, Aeschbacher S, Dittrich T, Polymeris A, Coslovksy M, Blum M, Rodondi N, Reichlin T, Moschovitis G, Wuerfel J, Lyrer P, Fischer U, Conen D, Kästner P, Ziegler A, Osswald S, Kühne M, Bonati L, Swiss-AF investigators. Biomarker, Imaging, and Clinical Factors Associated With Overt and Covert Stroke in Patients With Atrial Fibrillation. *Stroke* 2023

Moutzouri E, Glutz M, Abolhassani N, Feller M, Adam L, Gencer B, Del Giovane C, Bétrisey S, Paladini R, Hennings E, Aeschbacher S, Beer J, Moschovitis G, Seiffge D, De Marchis G, Coslovsky M, Reichlin T, Conte G, Sinnecker T, Schwenkglens M, Bonati L, Kästner P, Aujesky D, Kühne M, Osswald S, Fischer U, Conen D, Rodondi N. Association of statin use and lipid levels with cerebral microbleeds and intracranial hemorrhage in patients with atrial fibrillation: A prospective cohort study. *Int J Stroke* 2023:17474930231181010.

Hennings E, Blum S, Aeschbacher S, Coslovsky M, Knecht S, Eken C, Lischer M, Paladini R, Krisai P, Reichlin T, Rodondi N, Beer J, Ammann P, Conte G, De Perna M, Kobza R, Blum M, Bossard M, Kästner P, Ziegler A, Müller A, Bonati L, Pfister O, Zuern C, Conen D, Kühne M, Osswald S, Swiss-AF Investigators. Bone Morphogenetic Protein 10-A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation. *J Am Heart Assoc* 2023; 12:e028255.

Blum S, Conen D, Osswald S, Sticherling C, Baguley F, Kästner P, Blum M, Bonati L, Moschovitis G, Ammann P, Beer J, Rodondi N, Kühne M, Meyre P, Aeschbacher S, BEAT-AF and Swiss-AF Investigators. Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. *Heart Rhythm* 2020

Dörner T, Peters M, Schwenke H, Rubbert-Roth A, Krüger K, Kurthen R, Kellner H, Kästner P, Engel A, Schmalzing M, Iking-Konert C, Burmester G, Schulze-Koops H, Tony H. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). *Clin Exp Rheumatol* 2019; 37:937-945.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)